ABBVAbbVieNot started yet
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-Squamous Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 660 (planned)
- Started
- Jan 6, 2027
- Main results expected
- Mar 2030
- Fully finished
- Apr 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response (OR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measured over: Up to Approximately 24 Months
Overall Survival (OS)
Measured over: Up to Approximately 50 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07821684 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC